All In Biotech

Drug Trial Radar · NCT05280548

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

104

Actual

Start

May 3, 2022

Primary completion

May 22, 2026

Study completion Dec 6, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy. * Study visits will take place approximately every 3 to 6 months * Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to additional 45 months with the total study duration up to 5.3 years maximum.

Conditions

  • Fabry Disease

Interventions

  • Venglustat (GZ402671)Drug

    Tablet; Oral

  • Agalsidase alfaDrug

    Concentrate for solution for infusion; IV infusion

  • Agalsidase beta (GZ419828)Drug

    Powder for concentrate for solution for infusion; IV infusion

  • MigalastatDrug

    Hard capsules; Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Slope of left ventricular mass index as measured by cardiac magnetic resonance imaging (MRI) (central reading)Time frame: from baseline to 18 months

Locations

54 sites in 19 countries. Site status is shown where the registry gives one.

  • University of Alabama -The Kirklin Clinic- Site Number : 8400010

    Birmingham, Alabama

  • University of California Los Angeles Medical Center- Site Number : 8400008

    Los Angeles, California

  • Emory University School of Medicine - Atlanta- Site Number : 8400009

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005

    Chicago, Illinois

  • Maryam Banikazemi, MD- Site Number : 8400001

    Hawthorne, New York

  • Renal Disease Research Institute- Site Number : 8400012

    Dallas, Texas

  • University of Utah Health Hospital- Site Number : 8400006

    Salt Lake City, Utah

  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004

    Fairfax, Virginia

  • Investigational Site Number : 0400001

    Graz, Austria

  • Investigational Site Number : 1240003

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240006

    Edmonton, Alberta, Canada

  • Investigational Site Number : 1240002

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240005

    Toronto, Ontario, Canada

  • Investigational Site Number : 1560002

    Beijing, China

  • Investigational Site Number : 1560005

    Beijing, China

  • Investigational Site Number : 1560001

    Chengdu, China

  • Investigational Site Number : 1560007

    Guangzhou, China

  • Investigational Site Number : 1560003

    Shanghai, China

  • Investigational Site Number : 2030001

    Prague, Czechia

  • Investigational Site Number : 2080001

    Copenhagen, Denmark

  • Investigational Site Number : 2500001

    Garches, France

  • Investigational Site Number : 2760003

    Berlin, Germany

  • Investigational Site Number : 2760004

    Hochheim am Main, Germany

  • Investigational Site Number : 2760005

    Mainz, Germany

  • Investigational Site Number : 2760001

    Würzburg, Germany

  • Investigational Site Number : 3000002

    Athens, Greece

  • Investigational Site Number : 3000003

    Athens, Greece

  • Investigational Site Number : 3000001

    Heraklion, Greece

  • Investigational Site Number : 3800004

    Bologna, Italy

  • Investigational Site Number : 3800001

    Milan, Lombardy, Italy

  • Investigational Site Number : 3800002

    Naples, Napoli, Italy

  • Investigational Site Number : 3800003

    Naples, Napoli, Italy

  • Investigational Site Number : 3920004

    Fukuoka, Japan

  • Investigational Site Number : 3920001

    Tokyo, Japan

  • Investigational Site Number : 3920006

    Sapporo, Hokkaido, Japan

  • Investigational Site Number : 3920007

    Kagoshima, Kagoshima-ken, Japan

  • Investigational Site Number : 3920003

    Kagoshima, Kagoshima-ken, Japan

  • Investigational Site Number : 3920005

    Kawasaki, Kanagawa, Japan

  • Investigational Site Number : 3920002

    Sendai, Miyagi, Japan

  • Investigational Site Number : 5280001

    Amsterdam, Netherlands

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.